Skip to Content

Rule

New Animal Drugs; Change of Sponsor

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Final rule; technical amendment.

SUMMARY:

The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for 30 approved new animal drug applications (NADAs) from Pfizer, Inc., to Phibro Animal Health, Inc. The technical amendments made by this final rule are intended to provide accuracy and clarity to the agency's regulations.

DATES:

This rule is effective September 17, 2001.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Lonnie W. Luther, Center for Veterinary Medicine (HFV-102), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-0209.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

Pfizer, Inc., 235 East 42d St., New York, NY 10017-5755, has informed FDA that it has transferred ownership of, and all rights and interest in, the following NADAs to Phibro Animal Health, Inc., One Parker Plaza, Fort Lee, NJ 07024:

NADA No.Product Name
32-704Bloat Guard® Top Dressing
35-287OM-5 Premix
38-281Bloat Guard® Liquid Premix
41-061Mecadox® Premix 10
43-290Banminth® Premix 80
46-668Penicillin G Procaine 50% and 100% Type A Medicated Articles
91-467Stafac® 20, 500 Type A Medicated Articles
91-513Stafac® Type A Medicated Articles
92-286CTCL 10, 20, 30, 50, 70 Type A Medicated Article
92-287CTCL 50 MR, 100 MR Type A Medicated Article
92-444Rumatel® Premix 88
92-955Mecadox®/Banminth®
98-431Tylan® 10 Premix
99-006Terramycin®/Coban®
101-666Terramycin®/Robenz®
110-047Banminth®/Tylan®
116-044Banminth®/Lincomix®
120-724Stafac®/Coban®/3-Nitro®
122-481Stafac®/Coban®
122-608Stafac®/Avatec®
122-822Stafac®/Amprol HI-E®
138-828Stafac®/Biocox®
138-953Stafac®/Biocox®/3-Nitro®
140-448Biocox®/Terramycin®
140-940Aviax® Type A Medicated Article
140-998V-Max Type A Medicated Article
141-058Aviax®/BMD®/3-Nitro®
141-058Aviax®/BMD®/3-Nitro®
141-065Aviax®/BMD®
141-066Aviax®/3-Nitro®
141-114Aviax®/Stafac®

Accordingly, the agency is amending the regulations in §§ 520.1840, 558.58, 558.115, 558.128, 558.198, 558.311, 558.355, 558.360, 558.435, 558.450, 558.460, 558.465, 558.485, 558.515, 558.550, 558.555, 558.625, and 558.635 (21 CFR 520.1840, 558.58, 558.115, 558.128, 558.198, 558.311, 558.355, 558.360, 558.435, 558.450, 558.460, 558.465, 558.485, 558.515, 558.550, 558.555, 558.625, and 558.635) to reflect the transfer of ownership. In addition, §§ 520.1840 and 558.485 are being revised to reflect current format.

Section 558.450 is also being amended to remove the entries for combination uses of oxytetracycline (OTC) with monensin, provided under NADA 99-066, because they are redundant with entries in § 558.355. The entry for the use of 400 grams per (g/) ton OTC with 90 to 110 g/ton monensin in § 558.450(d)(1)(vi) is an error created during prior revisions (61 FR 51588, Oct. 3, 1996). The correct drug levels, 200 g/ton OTC with 90 to 110 g/ton monensin, for the same indications are codified in Start Printed Page 47963§ 558.355(f)(1)(viii). The entry for the use of 500 g/ton OTC with 90 to 110 g/ton monensin in § 558.450(d)(1)(vii) is redundant with § 558.355(f)(1)(xxii).

This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

Start List of Subjects

List of Subjects

End List of Subjects Start Amendment Part

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine,

End Amendment Part Start Part

PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

End Part

1. The authority citation for 21 CFR part 520 continues to read as follows:

Start Authority

Authority: 21 U.S.C. 360b.

End Authority Start Amendment Part

2. Section 520.1840 is amended by revising paragraphs (a), (b), and (c) to read as follows.

End Amendment Part
Poloxalene.

(a) Specifications. Polyoxypropylene-polyoxyethylene glycol nonionic block polymer.

(b) Sponsors. See sponsors in § 510.600(c) of this chapter for use as in paragraph (d) of this section.

(1) No. 000069 for use as in paragraphs (d)(1) and (d)(3) of this section.

(2) No. 017800 for use as in paragraph (d)(4) of this section.

(3) No. 036904 for use as in paragraph (d)(2) of this section.

(4) No. 066104 for use as in paragraph (d)(3) of this section.

(c) [Reserved]

* * * * *
Start Part

PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

End Part

3. The authority citation for 21 CFR part 558 continues to read as follows:

Start Authority

Authority: 21 U.S.C. 360b, 371.

End Authority
[Amended]

4. Section 558.58 Amprolium and ethopabate is amended in the table in paragraph (d)(1)(iii) under the “Limitations” column in the entry for “Virginiamycin 15” by removing “000069” and by adding in its place “066104”.

[Amended]

5. Section 558.115 Carbadox is amended in paragraph (a) by removing “000069” and by adding in its place “066104”.

[Amended]

6. Section 558.128 Chlortetracycline is amended in paragraph (a)(1) by removing “000069, 046573, and 053389” and by adding in its place “046573, 053389, and 066104”; and in the table in paragraph (d)(1) under the “Sponsor” column by removing “000069” wherever it occurs and by adding in its place in numerical sequence “066104”.

[Amended]

7. Section 558.198 Diclazuril is amended in the table in paragraphs (d)(1)(iv) and (d)(1)(v) by removing “000069” under the “Limitations” column and by adding in its place “066104”.

[Amended]

8. Section 558.311 Lasalocid is amended in paragraph (b)(2) by removing “000069” and by adding in its place “066104” and in the table in paragraph (e)(1)(xv) in the entry for “Virginiamycin 10 to 20” under the “Limitations” column by removing “000069” and by adding in its place “066104”.

[Amended]

9. Section 558.355 Monensin is amended in paragraphs (b)(5), (b)(12), (f)(1)(xxii)(b), and (f)(2)(iv)(b) by removing “000069” and by adding in its place “066104”; in paragraphs (f)(1)(xiii)(b) and (f)(1)(xxi)(b) by removing “000007” and by adding in its place “066104”; and in paragraph (f)(1)(xx)(b) by removing “as monensin sodium; as roxarsone” and by adding in its place “as monensin sodium provided by No. 000986 in § 510.600(c) of this chapter; as virginiamycin provided by No. 066104 in § 510.600(c) of this chapter; roxarsone”.

[Amended]

10. Section 558.360 Morantel tartrate is amended in paragraph (a) by removing “000069” and by adding in its place “066104”.

[Amended]

11. Section 558.435 Oleandomycin is amended in paragraph (a) by removing “000069” and by adding in its place “066104”.

[Amended]

12. Section 558.450 Oxytetracycline is amended in table 1 in paragraph (d)(1) by removing the entries for “Monensin 90 to 110 g/ton” in paragraphs (d)(1)(vi) and (d)(1)(vii); in paragraph (d)(1)(vii) in the entry for “Salinomycin 40 to 60 g/ton” by removing “000069” under the “Sponsor” column and by adding in its place in numerical sequence “066104”.

[Amended]

13. Section 558.460 Penicillin is amended in paragraph (b) by removing “000069” and by adding in its place “066104”.

[Amended]

14. Section 558.465 Poloxalene free-choice liquid Type C feed is amended in paragraph (a) by removing “000069” and by adding in its place “066104”.

15. Section 558.485 is amended by revising paragraphs (a), (b), and (d)(1) to read as follows:

Pyrantel.

(a) Specifications. Type A medicated articles containing 9.6, 19.2, 48, or 80 grams per pound pyrantel tartrate.

(b) Approvals. See sponsors in § 510.600(c) of this chapter for uses as in paragraph (e) of this section:

(1) No. 066104: 9.6, 19.2, and 80 grams per pound for use as in paragraph (e)(1) of this section.

(2) No. 001800: 9.6 grams per pound for use as in paragraphs (e)(1)(i) through (e)(1)(iii) of this section.

(3) Nos. 010439, 011490, 011749, 016968, 017473, 017519, 017790, 043733, 049685, 050568, 050639, and 051359: 9.6 and 19.2 grams per pound for use as in paragraphs (e)(1)(i) through (e)(1)(iii) of this section.

(4) No. 021676: 19.2 grams per pound for use as in paragraphs (e)(1)(i) through (e)(1)(iii) of this section.

(5) No. 017800: 19.2 and 48 grams per pound for use as in paragraphs (e)(1)(i) through (e)(1)(iii) of this section.

(6) Nos. 034936 and 046987: 9.6 and 19.2 grams per pound for use as in paragraphs (e)(1)(i) and (e)(1)(ii) of this section.

(7) Nos. 000069, 017135, and 062240: 48 grams per pound for use as in paragraph (e)(2) of this section.

* * * * *

(d) Special considerations. (1) See § 500.25 of this chapter. Consult a veterinarian before using in severely debilitated animals.

* * * * *
[Amended]

16. Section 558.515 Robenidine hydrochloride is amended in the table in paragraph (d) in the entry for “Oxytetracycline 400” under the “Sponsor” column by removing “000069” and by adding in its place “066104”.

Start Printed Page 47964
[Amended]

17. Section 558.550 Salinomycin is amended in paragraphs (d)(1)(x)(c) and (d)(1)(xii)(c) by removing “053571” and by adding in its place “066104”.

18. Section 558.555 is amended by revising paragraph (a); by removing paragraph (c); by redesignating paragraph (b) as paragraph (c); in paragraph (d) by removing “000069” wherever it appears and by adding in its place “066104”; and by adding new paragraph (b) to read as follows:

Semduramicin.

(a) Specifications. Type A medicated article containing 22.7 grams per pound (50 grams per kilogram) semduramicin sodium.

(b) Approvals. See No. 066104 in § 510.600(c) of this chapter for use as in paragraph (d) of this section.

* * * * *
[Amended]

19. Section 558.625 Tylosin is amended in paragraph (b)(25) by removing “000069” and by adding in its place “066104”.

[Amended]

20. Section 558.635 Virginiamycin is amended in paragraph (a)(1) by removing “000069” and by adding in its place “066104”.

Start Signature

Dated: August 31, 2001.

Claire M. Lathers,

Office of New Animal Drug Evaluation, Center for Veterinary Medicine.

End Signature End Supplemental Information

[FR Doc. 01-23044 Filed 9-14-01; 8:45 am]

BILLING CODE 4160-01-S